Mumbai: Several Type 1 diabetes patients in India are upset with discontinuation of a continuous glucose monitoring (CGM) sensor that has been the "mo.
Zacks Investment Research on MSN3h
DexCom CGM Sensor Sales to Continue Despite FDA Warning LetterDexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...
DexCom's growth is slowing with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% ...
Medicare Part B started covering continuous glucose monitors for diabetes within the last decade. Abbott’s Freestyle Libre, approved by the FDA in 2017, is one such device. A diabetes diagnosis ...
The latest version of Abbott's FreeStyle Libre continuous glucose ... scanned of 'flash' CGM if it is available for the same or lower acquisition cost, according to the draft, which is due to ...
Zacks Investment Research on MSN2d
EPD Expansion Supports Abbot Stock, Macro Issues PrevailAbbott's ABT diversified business portfolio is well-positioned to drive momentum. However, the international business environment continues to be challenging globally. The stock carries a Zacks Rank ...
Good day and welcome to the Tandem Diabetes Fourth Quarter and Year-End 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there ...
Impaired glucose homeostasis leads to numerous complications, with coronary artery disease (CAD) being a major contributor to healthcare costs worldwide ... study analyzed a previously reported CGM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback